# NCT03474107 (NCT03474107)

> A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03474107
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Ureteral Cancer; Urothelial Cancer; Bladder Cancer
- Interventions: Enfortumab Vedotin; Docetaxel; Vinflunine; Paclitaxel
- Enrollment: 608
- Primary outcome: Overall Survival (OS)

## Commentary we found

- Podcasts: 44
- YouTube: 32
- X threads: 27
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03474107

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03474107", "email": "<work email>"}; the inbox owner confirms by the emailed link.